Trial Profile

A retrospective study to determine efficacy and safety of belimumab in patients with lupus nephritis in China

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary)
Indications Lupus nephritis; Systemic lupus erythematosus
Focus Adverse reactions; Therapeutic Use

Most Recent Events

31 Jan 2023 New trial record
28 Jan 2023 Primary endpoint has been met (estimated glomerular filtration rate at 48 weeks) , according to Results published in the International Journal of Clinical Pharmacology and Therapeutics
28 Jan 2023 Primary endpoint has been met (24-hour proteinuria at 48 weeks) , according to Results published in the International Journal of Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com